Page last updated: 2024-11-08

cmx 001

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID483477
CHEMBL ID203321
SCHEMBL ID139922
MeSH IDM0517474

Synonyms (50)

Synonym
[(1s)-1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methyl-(3-hexadecoxypropoxy)phosphinic acid
3-((2s)-2-{[(3-hexadecyloxypropoxy)(hydroxyphosphoryl)]methoxy}-3-hydroxypropyl)-6-amino-3-hydropyrimidin-2-one
hdp-cdv
cidofovir prodrug
cmx001
hexadecyloxypropyl-cidofovir
1-o-hexadecylpropanediol-cdv
hdp-hpmpc
brincidofovir
cmx-001
cidofovir hexadecyloxypropyl ester
[(2s)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
hdp-cidofovir
hexadecyloxypropyl cidofovir
cmx 001
CHEMBL203321
444805-28-1
hexadecyloxypropyl - cidofovir
unii-6794o900ax
phosphonic acid, p-(((1s)-2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, mono(3-(hexadecyloxy)propyl) ester
6794o900ax ,
cidofovir-hdp
brincidofovir [usan:inn]
SCHEMBL139922
brincidofovir [who-dd]
brincidofovir [inn]
brincidofovir [orange book]
brincidofovir [usan]
tembexa
brincidofovir (usan)
D10547
3-(hexadecyloxy)propyl hydrogen ((((s)-1-(4-amino-2-oxopyrimidin-1(2h)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonate
DTXSID60196190 ,
brincidofovir (cmx-001)
DB12151
brincidofovir; cmx001
EX-A2366
WXJFKKQWPMNTIM-VWLOTQADSA-N
BCP08580
Q15411004
A13326
gtpl11556
NCGC00686671-01
hdp-cdvcmx001
AC-36043
nsc-783202
nsc783202
cmx001;hdp-cdv
dtxcid70118681
brincidofovirum

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No serious adverse events were attributed to CMX001 during therapy."( Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.
Anderson, M; Florescu, DF; Graham, ML; Guzman-Cottrill, JA; Johnston, C; Kurtzberg, J; Lanier, R; Lewinsohn, DA; Mommeja-Marin, H; Neely, MN; Painter, W; Papanicolaou, G; Pergam, SA; Qiu, F; Rigdon, J; Sande, J; van der Horst, C; Way, S, 2012
)
0.38
" No adverse events occurred that prevented dose escalation."( First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.
Godkin, S; Lampert, B; Painter, G; Painter, W; Robertson, A; Trost, LC, 2012
)
0.38
" Analysis of renal function and adverse events from 3 BCV clinical studies in immunocompromised adult and pediatric subjects indicated little to no evidence of associated nephrotoxicity."( Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies.
Brundage, TM; Momméja-Marin, H; Morrison, ME; Tippin, TK, 2016
)
0.43
" The most common adverse events were mild gastrointestinal events and asymptomatic, transient, and reversible elevations in serum transaminases."( Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox.
Brundage, T; Chittick, G; Morrison, M; Nichols, WG, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" The objectives of the study were to evaluate the safety and pharmacokinetic parameters of CMX001 after single and multiple doses."( First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.
Godkin, S; Lampert, B; Painter, G; Painter, W; Robertson, A; Trost, LC, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" However, (S)-HPMPA is not orally bioavailable and has not been developed for clinical use."( Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses.
Beadle, JR; Ciesla, SL; Hartline, C; Hostetler, KY; Keith, KA; Kern, ER; Wan, WB, 2006
)
0.33
" However, the ether lipid esters of (S)-HPMPA, hexadecyloxypropyl-[(S)-HPMPA] [HDP-(S)-HPMPA] and octadecyloxyethyl-[(S)-HPMPA] [ODE-(S)-HPMPA], had significantly enhanced activity in vitro and are orally bioavailable in mice."( Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
Beadle, JR; Collins, DJ; Herrod, BP; Hostetler, KY; Keith, KA; Kern, ER; Quenelle, DC; Trahan, J, 2007
)
0.34
" An ether-lipid analogue of CDV, CMX001 (HDP-CDV), has potent antiviral activity against a range of DNA viruses including poxviruses, excellent oral bioavailability and minimal nephrotoxicity."( Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
Almond, M; Buller, RM; Lampert, B; Oberle, C; Painter, G; Parker, S; Robertson, A; Touchette, E; Trost, LC, 2008
)
0.35
" We evaluated the in vivo efficacy of an orally bioavailable analog of cidofovir, hexadecyloxypropyl-cidofovir (HDP-CDV), against guinea pig CMV (GPCMV) in a guinea pig model of congenital CMV infection."( Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
Beadle, JR; Bernstein, DI; Bravo, FJ; Cardin, RD; Hostetler, KY, 2011
)
0.37
" CMX001 is an orally bioavailable lipid conjugate of cidofovir that is substantially less nephrotoxic than the parent drug and has excellent antiviral activity against all the human herpesviruses."( CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.
Hartline, CB; Kern, ER; Lanier, ER; Prichard, MN; Quenelle, DC, 2011
)
0.37
" We describe the clinical experience of 13 immunocompromised patients who received CMX001 (hexadecyloxypropyl cidofovir), an orally bioavailable lipid conjugate of cidofovir, for adenovirus disease."( Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.
Anderson, M; Florescu, DF; Graham, ML; Guzman-Cottrill, JA; Johnston, C; Kurtzberg, J; Lanier, R; Lewinsohn, DA; Mommeja-Marin, H; Neely, MN; Painter, W; Papanicolaou, G; Pergam, SA; Qiu, F; Rigdon, J; Sande, J; van der Horst, C; Way, S, 2012
)
0.38
" We conclude that CMX001 is orally bioavailable and well tolerated in healthy volunteers at doses up to 2 mg/kg, approximately 140 mg in a typical adult."( First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.
Godkin, S; Lampert, B; Painter, G; Painter, W; Robertson, A; Trost, LC, 2012
)
0.38
" Novel therapeutic approaches including CMX001, a new orally bioavailable lipid conjugate of cidofovir and the transfer of adenovirus-specific donor T cells in the context of allogeneic stem cell transplantation are discussed."( Diagnosis and treatment of adenovirus infection in immunocompromised patients.
Boztug, H; Lion, T; Matthes-Martin, S, 2013
)
0.39
"Brincidofovir (BCV) is an orally bioavailable lipid conjugate of cidofovir (CDV) with increased in vitro potency relative to CDV against all 5 families of double-stranded DNA viruses that cause human disease."( Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies.
Brundage, TM; Momméja-Marin, H; Morrison, ME; Tippin, TK, 2016
)
0.43
" Brincidofovir (BCV) is a lipid formulation of CDV, which has an improved oral bioavailability and favorable toxicity profile compared with CDV."( Adenovirus infection in pediatric transplant recipients: are effective antiviral agents coming our way?
Green, M; Lopez, SMC; Michaels, MG, 2018
)
0.48
" Brincidofovir (BCV) is an orally bioavailable lipid conjugate of cidofovir, which has activity against adenoviruses."( Brincidofovir as a Salvage Therapy in Controlling Adenoviremia in Pediatric Recipients of Hematopoietic Stem Cell Transplant.
Kinsey, S; Meena, JP; Phillips, RS, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"We have used these biomarkers to establish the optimal dosing regimen for treatment and reveal that a single dose of 25 mg/kg of CMX001 can be efficacious at treating lethal mousepox when administered on days 4 or 5 post-infection."( Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Buller, RM; Lanier, R; Oberle, C; Painter, G; Parker, S; Robertson, A; Schriewer, J, 2008
)
0.35
" Here we extend these studies by exploring different dosing regimens and performing randomized, blinded, placebo-controlled studies."( Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Adams, MM; Burrage, AM; Foster, S; Gray, SA; Lampert, B; Lanier, R; Lindsey, SF; Manning, BR; Moyer, RW; Painter, G; Rice, AD; Robertson, A; Smith, AJ; Swetnam, D; Wallace, G, 2011
)
0.37
" Bodyweight-adjusted dosing was used for patients weighing <50 kg at enrolment."( Experimental Treatment of Ebola Virus Disease with Brincidofovir.
Antierens, A; Carson, G; Castle, L; Ciglenecki, I; Dunning, J; Grove, J; Horby, PW; Howell-Jones, R; Kanapathipillai, R; Kennedy, SB; Lang, T; Olliaro, P; Pardinaz-Solis, R; Scott, J; Whitehead, J, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (105)

Assay IDTitleYearJournalArticle
AID373579Cytotoxicity against HFF cells after 7 days by neutral red assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373585Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 1 day of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373576Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587952Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam liver viral log10 genome copies/ug of DNA at 4 mg/kg, po qd for 9 days measured 10 days post infectio2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587878Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam liver with detectable viral DNA at 4 mg/kg, po qd for 5 days measured 10 days post infection by real-2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373581Selectivity index, ratio CC50 for HFF cells to EC50 for Vaccinia virus WR2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373577Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587856Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as reduction in viral DNA level in dam spleen at 20 mg/kg, po once at 24 hrs post infection and once at 7 da2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587874Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as dam kidney toxicity at 4 mg/kg, po treatment started at 24 hrs post infection for 9 consecutive days2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596270Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID587863Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as reduction in pups with detectable viral DNA at 20 mg/kg, po once at 24 hrs post infection and once at 7 d2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373584Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 1 day of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373580Selectivity index, ratio CC50 for HFF cells to EC50 for Vaccinia virus Copenhagen2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587879Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam liver with detectable viral DNA at 4 mg/kg, po qd for 9 days measured 10 days post infection by real-2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587867Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as decreased animal activity at 4 mg/kg, po treatment started at 24 hrs post infection for 5 consecutive days2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587877Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as reduction in dam viremia at 4 mg/kg, po qd for 5 days2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587873Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as dam liver toxicity at 4 mg/kg, po treatment started at 24 hrs post infection for 9 consecutive days2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373598Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 3 mg/kg, po treated for 5 days after 3 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID1321305Tmax in human at 0.025 to 2 mg/kg dosed as single and multiple doses2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.
AID587866Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as animal weight loss at 20 mg/kg, po once at 24 hrs post infection and once 7 days post infection2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373445Cytotoxicity against HFF cells after 7 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID587858Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as reduction in viral DNA level in pup spleen at 20 mg/kg, po once at 24 hrs post infection and once at 7 da2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596262Metabolic stability in rat liver S9 fraction assessed as compound disappearance at 1 uM after 90 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID587951Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam liver viral log10 genome copies/ug of DNA at 4 mg/kg, po qd for 5 days measured 10 days post infectio2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373595Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 3 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID596259Metabolic stability in guinea pig liver S9 fraction assessed as compound disappearance at 10 uM after 90 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID373603Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 6 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587876Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as pup kidney toxicity at 4 mg/kg, po treatment started at 24 hrs post infection for 9 consecutive days2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373608Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 3 mg/kg, po treated for 5 days after 6 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID596265Selectivity index, ratio of CC50 for human HFF cells to EC50 for Cowpox virus (Brighton Red)2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID373582Selectivity index, ratio CC50 for HFF cells to EC50 for Cowpox virus Brighton2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID596253Metabolic stability in rhesus monkey liver S9 fraction assessed as compound remaining at 1 uM after 90 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID373596Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 0.3 mg/kg, po treated for 5 days after 3 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587862Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as increase in pup survival at 20 mg/kg, po once at 24 hrs post infection and once at 7 days post infection2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587852Cytotoxicity against guinea pig CCL158 cells after 10 days by crystal violet staining2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587854Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as pregnancy outcome measured as live-born pups at 20 mg/kg, po once at 24 hrs post infection and once 7 day2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373442Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID587884Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as fetus spleen with detectable viral DNA at 4 mg/kg, po qd for 5 days measured 10 days post infection by re2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID261840Antiviral activity against MCMV Smith replication2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses.
AID373440Selectivity index, ratio of CC50 for HFF cells to EC50 for Vaccinia virus WR2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID587869Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as low birth weight pups at 20 mg/kg, po once at 24 hrs post infection and once 7 days post infection (Rvb = 107 +/- 10 g)2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587864Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as pregnancy outcome measured as live-born pups at 4 mg/kg, po treatment started at 24 hrs post infection fo2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596261Metabolic stability in rat liver S9 fraction assessed as compound disappearance at 10 uM after 90 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID587883Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam spleen with detectable viral DNA at 4 mg/kg, po qd for 9 days measured 10 days post infection by real2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID392504Antiviral activity against Cowpox virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID373578Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587885Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as fetus spleen with detectable viral DNA at 4 mg/kg, po qd for 9 days measured 10 days post infection by re2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373736Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 0.3 mg/kg, po treated for 5 days after 6 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587853Selectivity index, ratio of CC50 for guinea pig CCL158 cells to IC50 for Guinea pig cytomegalovirus strain 221222011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373444Selectivity index, ratio of CC50 for HFF cells to EC50 for Vaccinia virus Copenhagen2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID596267Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID596268Selectivity index, ratio of CC50 for african green monkey BSC1 cells to EC50 for Ectromelia virus Moscow2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID261844Antiviral activity against Cowpox virus Brighton replication in HFF cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses.
AID587886Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam placenta with detectable viral DNA at 4 mg/kg, po qd for 5 days measured 10 days post infection by re2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587953Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as fetus liver viral log10 genome copies/ug of DNA at 4 mg/kg, po qd for 5 days measured 10 days post infect2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596252Metabolic stability in human liver S9 fraction assessed as compound remaining at 1 uM after 90 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID373605Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 0.3 mg/kg, po treated for 5 days after 6 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587955Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam spleen viral log10 genome copies/ug of DNA at 4 mg/kg, po qd for 5 days measured 10 days post infecti2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596266Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID587954Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as fetus liver viral log10 genome copies/ug of DNA at 4 mg/kg, po qd for 9 days measured 10 days post infect2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587872Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as adverse effect on complete blood count in new born pups at 4 mg/kg, po treatment started at 24 hrs post infection for 9 con2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID1321306Half life in human at 0.025 mg/kg dosed as single and multiple doses2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.
AID596264Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID373599Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 3 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587875Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as pup liver toxicity at 4 mg/kg, po treatment started at 24 hrs post infection for 9 consecutive days2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373441Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID587956Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam spleen viral log10 genome copies/ug of DNA at 4 mg/kg, po qd for 9 days measured 10 days post infecti2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587851Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected guinea pig CCL158 cells assessed as plaque reduction measured after 10 days by plaque reduction assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587881Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as fetus liver with detectable viral DNA at 4 mg/kg, po qd for 9 days measured 10 days post infection by rea2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587870Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as low birth weight pups at 4 mg/kg, po treatment started at 24 hrs post infection for 5 consecutive days (Rvb = 107 +/- 10 g)2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587855Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as reduction in dam blood viral log10 genome copies/ug of DNA at 20 mg/kg, po once at 24 hrs post infection 2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373439Selectivity index, ratio of CC50 for HFF cells to EC50 for Cowpox virus Brighton2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID587868Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as animal weight loss at 4 mg/kg, po treatment started at 24 hrs post infection for 5 consecutive days2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587880Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as fetus liver with detectable viral DNA at 4 mg/kg, po qd for 5 days measured 10 days post infection by rea2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596256Metabolic stability in rhesus monkey liver S9 fraction assessed as compound disappearance at 1 uM after 20 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID596269Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID1321307Half life in human at 1.5 mg/kg dosed as single and multiple doses2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.
AID261838Antiviral activity against HCMV AD-169 replication2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses.
AID373594Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 3 mg/kg, po treated for 5 days after 3 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373604Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 1 mg/kg, po treated for 5 days after 6 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587859Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as reduction in viral DNA level in pup liver at 20 mg/kg, po once at 24 hrs post infection and once at 7 day2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596258Metabolic stability in human liver S9 fraction assessed as compound disappearance at 1 uM after 90 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID373735Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 6 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587860Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as pup spleen containing detectable viral DNA at 20 mg/kg, po once at 24 hrs post infection and once at 7 da2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587882Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam spleen with detectable viral DNA at 4 mg/kg, po qd for 5 days measured 10 days post infection by real2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587958Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as fetus spleen viral log10 genome copies/ug of DNA at 4 mg/kg, po qd for 9 days measured 10 days post infec2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID373591Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 0.3 mg/kg, po treated for 5 days after 1 day of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587857Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as reduction in viral DNA level in dam liver at 20 mg/kg, po once at 24 hrs post infection and once at 7 day2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587871Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as adverse effect on complete blood count at 4 mg/kg, po treatment started at 24 hrs post infection for 9 consecutive days2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID597390Metabolic stability in rhesus monkey liver S9 fraction assessed as compound disappearance at 10 uM after 20 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID611773Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New prodrugs of Adefovir and Cidofovir.
AID261842Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses.
AID587861Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as pup liver containing detectable viral DNA at 20 mg/kg, po once at 24 hrs post infection and once at 7 day2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596263Selectivity index, ratio of CC50 for human HFF cells to EC50 for Vaccinia virus Copenhagen2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID373600Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 0.3 mg/kg, po treated for 5 days after 3 days of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373586Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mortality at 0.3 mg/kg, po treated for 5 days after 1 day of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID373590Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as virus-induced mean day of death at 1 mg/kg, po treated for 5 days after 1 day of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
AID587865Toxicity in Guinea pig cytomegalovirus strain 22122 infected second and third trimesters of pregnant Hartley guinea pig assessed as decreased animal activity at 20 mg/kg, po once at 24 hrs post infection and once 7 days post infection2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID596260Metabolic stability in guinea pig liver S9 fraction assessed as compound disappearance at 1 uM after 90 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID373443Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID596257Metabolic stability in human liver S9 fraction assessed as compound disappearance at 10 uM after 90 mins by HPLC/MS/MS2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
AID587957Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as fetus spleen viral log10 genome copies/ug of DNA at 4 mg/kg, po qd for 5 days measured 10 days post infec2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID587887Antiviral activity against Guinea pig cytomegalovirus strain 22122 infected in second and third trimesters of pregnant Hartley guinea pig assessed as dam placenta with detectable viral DNA at 4 mg/kg, po qd for 9 days measured 10 days post infection by re2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (119)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (6.72)29.6817
2010's86 (72.27)24.3611
2020's25 (21.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.15 (24.57)
Research Supply Index4.84 (2.92)
Research Growth Index5.44 (4.65)
Search Engine Demand Index22.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (4.17%)5.53%
Reviews27 (22.50%)6.00%
Case Studies20 (16.67%)4.05%
Observational1 (0.83%)0.25%
Other67 (55.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]